Are the current safety measures for the treatment of depression with esketamine sufficient?

Expert Opinion on Drug Safety 2026 Open access

Read full text
Authors: Kyle Valentino, Kayla M. Teopiz, Christine E. Dri, Jennifer Swainson, Yang Jing Zheng, Roger S. McIntyre
DOI: 10.1080/14740338.2026.2627184
Cited by: 1
References: 15

Abstract

1. Esketamine as monotherapy or adjunct to conventional antidepressants is proven efficacious in clinical trials in adults with treatment-resistant depression (TRD) and depression with high risk of...

Fields of Study & Subjects

Treatment of Major Depression Neurotransmitter Receptor Influence on Behavior Opioid Use Disorder Treatment

Publication details

Journal / source
Expert Opinion on Drug Safety
Publisher
Informa UK Limited
Volume
25
Issue
9
Pages
1615–1617
Publication date
3 February 2026
Language
EN